K. Luptakova

P. Hari, D. Faller, C. Asche, 2018, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Real-World and Clinical Trial Data in Relapsed/Refractory Multiple Myeloma (RRMM): Evaluating Treatment Duration and Comparing Effectiveness and Efficacy

M. Dimopoulos, A. Palumbo, J. Miguel, 2017 .

Lenalidomide enhances anti-myeloma cellular immunity

D. Kufe, J. Zwicker, R. Joyce, 2012, Cancer Immunology, Immunotherapy.

Lenalidomide Decreases PD-1 Expression, Depletes Regulatory T-Cells and Improves Cellular Response to a Multiple Myeloma/Dendritic Cell Fusion Vaccine In Vitro

D. Kufe, J. Rosenblatt, D. Avigan, 2010 .

Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1

J. Laubach, P. Richardson, P. Hari, 2018, Leukemia.

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

M. Dimopoulos, A. Palumbo, J. Laubach, 2018, Blood Cancer Journal.

Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France

M. Mohty, K. Davis, J. Kaye, 2019, Advances in hematology.

A 78-Year-Old Man with Acute Myeloid Leukemia (AML) and Acute Renal Failure

E. Tapper, R. Joyce, D. Tzachanis, 2014, The American journal of case reports.

Immune therapy in multiple myeloma.

D. Avigan, K. Luptakova, 2015, Clinical advances in hematology & oncology : H&O.

Chest Pain Suggestive of a Life-Threatening Condition: A Department of Medicine Morbidity and Mortality Conference.

Colin T Phillips, T. Stern, E. Tapper, 2016, Psychosomatics.

DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions

D. Neuberg, D. Kufe, D. DeAngelo, 2015 .

Clinical Trial Evaluating DC/AML Fusion Cell Vaccination In AML Patients

D. Neuberg, D. Kufe, D. DeAngelo, 2013 .

MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells.

P. Pandolfi, L. Yin, Keisuke Ito, 2013, Cancer research.

DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).

A. Nooka, A. Khot, M. Mateos, 2020 .

Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)

P. Richardson, B. Holkova, J. Opalinska, 2019, Blood.

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

M. Dimopoulos, A. Palumbo, J. Laubach, 2018, Blood Cancer Journal.

Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States

A. Palumbo, P. Hari, R. Rifkin, 2018, Clinical lymphoma, myeloma & leukemia.

Real-World Treatment Patterns and Health Care Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Cohort Review in France

M. Mohty, B. Seal, K. Davis, 2016 .

MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients

P. Trojer, S. Verstovsek, C. Harrison, 2020, Blood.

Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1

D. Kufe, I. Ghobrial, M. Bar‐Natan, 2014, British journal of haematology.

Primary Cardiac Burkitt Lymphoma Presenting with Abdominal Pain

R. Dewar, R. Joyce, D. Tzachanis, 2014, Case reports in hematology.

Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd, IRd) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Clinical Practice in the United States Vs Clinical Trial Experience

P. Hari, A. Chari, M. Blazer, 2017 .

The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies.

P. Hari, V. Morrison, M. Blazer, 2017, Journal of geriatric oncology.

DREAMM-9: Phase III study of belantamab mafodotin plus VRd versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma (TI NDMM).

E. Terpos, S. Usmani, G. Ferron-Brady, 2020 .

Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer

B. Monk, A. Oza, J. Berek, 2019, Gynecologic Oncology.

Uncovering the Blind Spot of Clinical Trials: First Report of Baseline Characteristics of Newly Diagnosed (ND) and Relapsed/Refractory (RR) Multiple Myeloma (MM) Patients (Pts) in Insight-MM, a Global, Prospective, Observational Study

H. Goldschmidt, M. Boccadoro, R. Hájek, 2017 .

Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM)

D. Esseltine, P. Ganly, N. Munshi, 2016 .

MPN-328: Pelabresib (CPI-0610) Improved Anemia Associated with Myelofibrosis: Interim Results from the Ongoing MANIFEST Phase 2 Study

S. Verstovsek, R. Hoffman, M. Talpaz, 2021 .

Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation

N. Munshi, J. Laubach, P. Richardson, 2012 .

DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM).

P. Richardson, B. Holkova, J. Opalinska, 2020 .

Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis

P. Hari, D. Faller, C. Asche, 2018, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Abstract NT-101: QUADRA: A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE SINGLE-AGENT NIRAPARIB TREATMENT IN PATIENTS WITH RELAPSED OVARIAN CANCER (ROC) WHO HAVE RECEIVED ≥3 PRIOR CHEMOTHERAPY REGIMENS

B. Monk, A. Oza, J. Berek, 2019 .

MUC 1 IS A POTENTIAL TARGET FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA STEM CELLS

Caterina, Rajabi, P. Pandolfi, 2014 .

Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.

D. Tenen, D. Costa, T. Shimamura, 2010, Blood.